CureVac to Present at BioCentury's 22nd Annual NewsMakers in the Biotech Industry Conference

Sep 03, 2015, 10:17 ET from CureVac

TUBINGEN, Germany, Sept. 3, 2015 /PRNewswire/ -- CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced that it will present at BioCentury's 22nd Annual NewsMakers in the Biotech Industry Conference to be held September 10, 2015 at the Millennium Broadway Hotel & Conference Center in New York City.

Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, will provide an overview of the company's business, industry-leading mRNA technology platform, and clinical-stage development pipeline during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event:


BioCentury's 22nd Annual NewsMakers in the Biotech Industry Conference

Date: 


Thursday, September 10, 2015

Time: 


9:30-10:00 am (Eastern Time) 

Location:


Millennium Broadway Hotel & Conference Center - Breakout Room 401

Address:


145 W 44th St, New York, NY 10036

Website:


www.biocentury.com/conferences/newsmakers/dates

About CureVac

CureVac is the leading company in messenger RNA (mRNA) based drugs with more than 15 years of expertise and the most advanced and broadest clinical pipeline in the industry. Until today CureVac received from dievini (Dietmar Hopp) and Bill & Melinda Gates Foundation approx. $220 million in equity investments.

Started in 2008 CureVac's mRNA products are subject of seven active clinical studies in more than 350 patients and healthy volunteers as of today, including a Phase IIb trial in prostate cancer. CureVac's mRNA technology is also the foundation for several high-profile partnerships involving multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, and Johnson & Johnson, as well as the Bill & Melinda Gates Foundation.

CureVac's proprietary technology platform utilizes natural, chemically unmodified mRNA, which studies have shown elicits greater therapeutic responses than chemically modified mRNA. CureVac's mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive®), molecular therapies designed to trigger the body's own production of therapeutic proteins (RNArt®), and RNA encoded antibodies (RNAntibody®). In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac will start the construction of an industrial scale production facility with a capacity of 30 million doses per year.

For more information, please visit www.curevac.com  

Media Contacts
Andrew Mielach
Tiberend Strategic Advisors, New York
+1 (212) 375-2694
amielach@tiberend.com

Verena Lauterbach, Manager Communications
CureVac GmbH, Tubingen, Germany
T: +49 (0) 7071 920 53 756
verena.lauterbach@curevac.com

SOURCE CureVac



RELATED LINKS

http://www.curevac.com